Search
Regulatory Affairs Insights
Scientists Found a Hidden Immune Organ Inside the Human Skull — What It Means for Brain Cancer Treatment and Regulatory Affairs
Scientists at Washington University School of Medicine in St. Louis have identified a **skull immune organ** — lymphoid structures inside the skull's bone marrow that act as first responders to brain disease. Published in *Nature* on 19 August 2026, the study shows microscopic channels carry antigens from the brain into skull marrow, where **T follicular helper cells** train **B cells** to fight threats, including glioblastoma, before distant lymph nodes react. Similar cells
Aug 2812 min read
FDA's Streamlined Nonclinical Safety Guidance for Monoclonal Antibodies: What It Means for Regulatory Affairs Professionals in 2026
In December 2025, the US Food and Drug Administration (FDA) published draft guidance — "Monoclonal Antibodies: Streamlined Nonclinical Safety Studies" (Docket FDA-2025-D-4634) — recommending that sponsors of monospecific monoclonal antibodies (mAbs) can reduce or eliminate long-duration animal toxicology studies, including in nonhuman primates (NHPs), where a robust weight-of-evidence (WoE) risk assessment supports doing so. It affects any company developing single-target mAb
Aug 2511 min read
Big Pharma's Q2 2026 Profits Are In — But Are Patients Still Losing Out on Affordable Medicines?
Big Pharma's Q2 2026 earnings** season, which concluded in early August, showed record profits and raised full-year guidance across most major manufacturers, even as US patient affordability data worsened. This affects patients paying out of pocket in the United States, pharmaceutical companies navigating new pricing regulation, and regulatory affairs professionals working across market access and lifecycle management. It matters now because the Medicare Drug Price Negotiatio
Aug 1413 min read
UK Launches New MHRA Regulatory Sandbox for AI-Enabled Medical Devices: What London Region I Means for Regulatory Affairs
The MHRA AI regulatory sandbox for medical devices, known as London Region I, allows up to 10 AI-enabled medical device manufacturers to deploy their technologies in real NHS clinical settings under regulatory oversight while generating real-world safety and effectiveness evidence. This affects AI medical device manufacturers, NHS providers across London, and UK regulatory affairs professionals working in medical devices. It applies from the Expression of Interest stage opene
Aug 1413 min read
eCTD 4.0 Explained: FDA, EMA and Japan Deadlines, Key Changes and What It Means for Regulatory Affairs Careers
**eCTD 4.0** is the next-generation global standard for electronic pharmaceutical regulatory submissions, replacing the document-centric **eCTD 3.2.2** format used since 2008. It affects regulatory affairs professionals, publishing specialists and every company submitting dossiers to the **FDA**, **EMA**, **PMDA** and other health authorities. The **FDA** has accepted eCTD 4.0 for new applications since **16 September 2024**; **Japan** targets a mandate by **April 2026**; and
Aug 1212 min read
The European Biotech Act 2026: What the New EU Biotechnology Framework Means for Pharma, Biotech and Regulatory Affairs Careers
The **European Biotech Act** is a European Commission legislative proposal, published as **COM(2025) 1022 final on 16 December 2025**, designed to close the EU's competitiveness gap in health biotechnology against the US and China. It affects pharmaceutical companies, biotech start-ups, investors and regulatory affairs professionals working with **ATMPs**, mRNA therapeutics, biologics and biosimilars. The Act introduces faster clinical trial timelines, EU-anchored investment
Aug 1212 min read
EMA OPEN Framework 2026 Update: What Pharma and Regulatory Affairs Teams Need to Know
The EMA OPEN framework (Opening Procedures at EMA to Non-EU Authorities) allows the European Medicines Agency (EMA) to run near-concurrent scientific assessments of certain medicines alongside seven non-EU regulatory partners, while each authority keeps full independence over its own decision. Originally piloted for COVID-19 medicines in December 2020, it was expanded to a wider range of therapeutic areas on 20 July 2023 and remains the operational basis for cross-border coll
Aug 511 min read
The EU HTA Regulation Is Reshaping How Clinical Evidence Supports Market Access Across Europe
On 30 April 2026, a milestone quietly passed that will redefine how innovative medicines reach patients across the European Union. The HTA Coordination Group (HTACG) approved the very first Joint Clinical Assessment (JCA) report in history — covering tovorafenib (Ojemda®), Ipsen's treatment for paediatric low-grade malignant glioma. Completed well within the 30-day timeline from marketing authorisation, it marked the first real-world product of a regulatory and market access
Jul 2814 min read
FDA Approves Tregzi (Orca-T) for GvHD Prophylaxis
The US Food and Drug Administration (FDA) approved Tregzi (Orca-T) on 30 June 2026, making it the first regulatory T cell-based immunotherapy authorised to improve chronic graft-versus-host disease (cGvHD)-free survival in adults undergoing matched donor allogeneic haematopoietic stem cell transplantation (allo-HSCT) for haematological malignancies. Developed by Orca Biosystems, Inc. (Orca Bio), Tregzi combines purified haematopoietic stem and progenitor cells (HSPCs), regula
Jul 2812 min read
Guiding Principles of Good AI Practice in Drug Development: What Every Regulatory Professional Needs to Know
In January 2026, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) jointly published one of the most significant regulatory science documents in recent memory: Guiding Principles of Good AI Practice in Drug Development. For the first time, the world's two most influential regulatory authorities have aligned on a shared framework governing how artificial intelligence must be developed, validated, documented, and managed across the entire pharm
Jul 912 min read
Revising EU GMP Annex 15: What the Concept Paper Means for the Industry
In January 2026, the EMA GMP/GDP Inspectors Working Group and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) jointly published a concept paper proposing the most significant revision to EU GMP Annex 15 in over a decade. The public consultation that followed — open from 9 February to 9 April 2026 — has generated substantial industry debate, and for good reason. What is being proposed is not a cosmetic update to existing guidance. It is a structural overhaul that w
Jul 912 min read
Joint Scientific Consultations (JSCs): What They Are and Who They Can Help
If you have spent any time navigating the EU Health Technology Assessment (HTA) landscape in 2025 or 2026, you will have encountered a question that stops many development teams in their tracks: how do we design a clinical trial that satisfies both the EMA for marketing authorisation and EU HTA bodies for the Joint Clinical Assessment — when their evidence requirements do not always align? The answer, in regulatory terms, is the Joint Scientific Consultation (JSC) — one of
Jul 816 min read
New PRIME Tools to Accelerate Development of Medicines in the EU: What It Means for Industry and Regulatory Careers
In March 2026, the European Medicines Agency (EMA) made a landmark announcement. After completing a two-year pilot programme, the agency formally launched three major new features under its PRIME (PRIority MEdicines) scheme — powerful tools designed to improve how innovative medicines reach patients across the European Union. For pharmaceutical developers, biotech companies, and the regulatory professionals who support them, this is not a routine administrative update. It rep
Jul 213 min read
Type IA Variations: Why "Simple" Variations Are Never as Simple as They Look
Ask any experienced regulatory affairs professional about Type IA variations and most will tell you the same thing: they look easy, they are not. Known in the industry as "do and tell" procedures, Type IA variations represent the process by which pharmaceutical companies make minor changes to their marketing authorisation (MA) dossiers — implementing the change first, then notifying the relevant regulatory authority. No prior approval needed. In theory, this is the most strai
Jun 2314 min read